Capital Investment Advisory Services, LLC Avadel Pharmaceuticals PLC Transaction History

Capital Investment Advisory Services, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 17, 2019	SELL	$1.92 - $4.47 $384 - $894	-200 Closed	0 $0
Q2 2019 Aug 08, 2019	SELL	$1.09 - $3.19 $218 - $638	-200 Reduced 50.0%	200 $0
Q1 2019 Apr 23, 2019	SELL	$1.44 - $3.29 $288 - $658	-200 Reduced 33.33%	400 $1,000
Q4 2018 Feb 04, 2019	BUY	$1.74 - $4.66 $1,044 - $2,796	600 New	600 $2,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Capital Investment Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Investment Advisory Services, LLC with notifications on news.